Nancy Stuart - 05 Jan 2022 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC.

Reporting relationship: Chief Operating Officer
Issuer ticker: N/A
Reported as of: 05 Jan 2022
Net transaction value: -$9,232
SEC form: 4
Accepted by SEC: 07 Jan 2022, 15:20:51 UTC
Next SEC filing: 01 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey A. Munsie, attorney-in-fact

Key filing fact

Nancy Stuart filed Form 4 for CONCERT PHARMACEUTICALS, INC. on 07 Jan 2022.

Key facts

This page summarizes Nancy Stuart's Form 4 filing for CONCERT PHARMACEUTICALS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Jan 2022, 15:20.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$9,232.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNCE transaction

Common Stock

Sale

Transaction value: $9,232
Shares: -2,894
Change %: -1.7%
Price: $3.19
Shares after: 170,386
Date: 05 Jan 2022
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This sale was effected pursuant to a Rule 10b5-1 trading plan.

Footnote F2

These shares were sold to satisfy tax obligations associated with the vesting of restricted stock units.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $3.07 to $3.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.